Professor Rahim Sorouri, the honored general director of the Pasteur Institute of Iran, on 16.07.2022, while visiting the vaccination department, received the fourth dose of PastoCovac vaccine.

As for the PastoCovac vaccine, it should be noted that currently, the official permission to inject the PastoCovac as a booster dose of all vaccines has been announced in the country and with the availability of this vaccine throughout the country, people can receive this vaccine with suitable and safe efficacy as the third or fourth booster dose of all vaccines.

In the phase 3 clinical trial study of this vaccine in Iran, about 66% effectiveness of the vaccine was observed in symptomatic forms and more than 95% effectiveness in preventing severe and hospitalized forms was observed. Presently, in addition to adults, all children over 5 years old can also receive this vaccine.

The PastoCovac vaccine creates effective and stable immunity against the virus that causes Covid-19 as a booster vaccine; furthermore, the permission to use PastoCovac vaccine as a booster dose of all vaccines used in the country has been notified to the country's universities of medical sciences. Studies have shown that the PastoCovac vaccine produced in the Pasteur Institute of Iran, which has a recombinant protein platform, and its safety and high efficiency have been shown in clinical studies, creates effective and stable immunity against the virus that causes Covid-19 as a booster vaccine.

Meanwhile, the average antibody after receiving the booster dose of the PastoCovac vaccine, in the recipients of the first two doses of the Sinopharm vaccine, was more than 20 times more than the people who had received the booster dose of the Sinopharm vaccine. In this study, the percentage of seroconversion (a 4-fold increase in antibody compared to the baseline value) of antibody in the recipients of the PastoCovac booster dose was more than 3 times that of the Sinopharm vaccine group.

In another study conducted on volunteers who received the first two doses of the vaccine, it was also shown that the increase in antibody titer in the group receiving the Covid-19 vaccine produced by the Pasteur Institute of Iran was more than double that of the group receiving the AstraZeneca vaccine. Also, the results of the immune stability evaluation in people who received 3 doses of the vaccines produced by the Pasteur Institute of Iran, have shown that six months after the third dose, an acceptable immune response was still maintained in the recipients.

 These studies have shown that the efficacy of Covid-19 vaccines jointly produced by Iran's Pasteur Institute and Cuba's Finlay Institute as a booster dose in stimulating the immune system is significantly higher than booster vaccines such as Sinopharm and AstraZeneca. In these studies, it has also been determined that the effectiveness of the booster dose of PastoCovac and PastoCovac-plus vaccines is similar to each other, and no specific side effects have been reported following their injection.